2410 — TYK Medicines Cashflow Statement
0.000.00%
- HK$10.00bn
- HK$9.70bn
- CNY0.11m
Annual cashflow statement for TYK Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | — |
Source: | PROSPECTUS | PROSPECTUS | |
Standards: | IFRS | IFRS | — |
Status: | Final | Final | fx Preliminary |
Net Income/Starting Line | -312 | -383 | — |
Depreciation | |||
Amortisation | |||
Non-Cash Items | 77.1 | 104 | — |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | -1.66 | 51 | — |
Change in Accounts Receivable | |||
Change in Payable / Accrued Expenses | |||
Net Change in Other Assets & Liabilities | |||
Cash from Operating Activities | -220 | -201 | — |
Capital Expenditures | -88.2 | -77.3 | — |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | -70 | 150 | — |
Sale of Fixed Assets | |||
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Other Investing Cash Flow | |||
Cash from Investing Activities | -158 | 73 | — |
Financing Cash Flow Items | 27.8 | 55.5 | — |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 351 | 224 | — |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -27.1 | 96.1 | — |